ClinicalTrials.gg
CompletedNCT01452711Updated Jun 21, 2013

Efficacy of TAK-438 Compared to AG-1749 (Lansoprazole) in the Treatment of Gastric Ulcer

A Phase 3 interventional study of TAK-438 and Placebo in Gastric Ulcer, sponsored by Takeda. Completed at 64 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2013-06-21.

Sponsored by Takeda · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
482
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing vonoprazan in Stomach Ulcer — 1 open to participants now, 1 under way, none of them phase 3. vonoprazan · Stomach Ulcer.

Enrollment
3rd of 10
482 · median 320
Started
2011
with 3 others
Phase 3
8 of 10
none open now
Registered
1st of 10
by date
Lead sponsor
8 of 10
Takeda

Among the 10 studies testing vonoprazan in Stomach Ulcer, this one is the 3rd largest by enrollment, is one of 4 that started in 2011, is one of 8 in phase 3, and was the 1st registered.

Stomach Ulcer

116 studies on the registry are indexed under Stomach Ulcer; 13 are open to participants now.

Browse Stomach Ulcer studies →

Open to participants now

1 of the 10 studies testing vonoprazan in Stomach Ulcer is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About vonoprazan

vonoprazan: first FDA approval 2022 (VOQUEZNA TRIPLE PAK). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 10 Stomach Ulcer studies recruiting now, 6 (60%) set no upper age limit and 3 (30%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing vonoprazan in Stomach Ulcer, or all of them as a file.
02

Study summary

The purpose of this study is to investigate the efficacy of TAK-438, once daily (QD), compared to lansoprazole in patients with gastric ulcer.

03

Conditions studied

  • Gastric Ulcer

Browse trials for

Keywords

  • Drug Therapy
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participants must have endoscopically confirmed gastric ulcers (mucosal defect with white coating) At least one ulcer with white coating of 5 mm or larger in size should be observed at baseline (Visit 1)
  2. Outpatient (including short inpatient for examination and others)

Exclusion criteria

Exclusion Criteria:

  1. Participants with a gastric ulcer which is suspected to be malignant on endoscopy at baseline (Visit 1)
  2. Participants with an Acute Gastric Mucosal Lesion (AGML) on endoscopy at baseline (Visit 1)
  3. Participants with a linear ulcer (including scarring) on endoscopy at baseline (Visit 1)
  4. Participants with a postoperative ulcer (e.g., Ulcer after EMR/ESD) on endoscopy at baseline (Visit 1)
  5. Participants with a duodenal ulcer on endoscopy at baseline (Visit 1)
  6. Participants with an ulcer for which medical treatment is not indicated (e.g., perforation, pyloric stenosis, duodenal stenosis, large hemorrhage)
  7. Participants who have received endoscopic hemostasis for gastric ulcer within 30 days prior to baseline (Visit 1)
  8. Participants with a previous or current history of Zollinger-Ellison syndrome, or other gastric acid hypersecretion disorders
  9. Participants who have received or who are scheduled to undergo surgery which affects gastric acid secretion (e.g., resection of upper gastrointestinal tract, vagotomy)
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
482 participants (actual)

Study arms

  • Experimental
    TAK-438 20 mg QD

    Drug: TAK-438 · Drug: Placebo

  • Active comparator
    Lansoprazole 30 mg QD

    Drug: Lansoprazole · Drug: Placebo

Interventions

  • TAK-438 20 mg, tablets, orally, once daily for up to 8 weeks.

  • DrugPlacebo

    Lansoprazole placebo-matching capsules, orally, once daily for up to 8 weeks.

  • Lansoprazole 30 mg, capsules, orally, once daily for up to 8 weeks.

    Also known as: AG-1749

  • DrugPlacebo

    TAK-438 placebo-matching tablets, orally, once daily for up to 8 weeks.

06

What researchers measure

Primary outcomes

  1. Endoscopic Healing Rate of Gastric Ulcer Over 8 weeks

    Endoscopic healing rate : Rate of participants who have endoscopically confirmed all of the white coatings disappeared.

    Time frame: 8 weeks

Secondary outcomes

  1. Endoscopic healing Rates of Gastric Ulcer on Endoscopy over 4 weeks

    Time frame: 4 weeks

  2. Endoscopic healing Rates of Gastric Ulcer on Endoscopy at week 2

    Time frame: 2 weeks

  3. Change from Baseline in the Incidence of Gastrointestinal Symptoms Associated with Gastric Ulcer

    Time frame: Baseline and 8 weeks

07

Study locations

64 sites
  • Toyota-shi, Aichi, Japan
  • Kamagaya-shi, Chiba, Japan
  • Kisarazu-shi, Chiba, Japan
  • Fukui-shi, Fukui, Japan
  • Fukuoka-shi, Fukuoka, Japan
  • Kitakyushu-shi, Fukuoka, Japan
  • Kurume-shi, Fukuoka, Japan
  • Onga-gun, Fukuoka, Japan
  • Tagawa-shi, Fukuoka, Japan
  • Yanagawa-shi, Fukuoka, Japan
  • Yukuhashi-shi, Fukuoka, Japan
  • Sappori-shi, Hokkaido, Japan
  • Kobe-shi, Hyogo, Japan
  • Nishinomiya-shi, Hyogo, Japan
  • Takarazuka-shi, Hyogo, Japan
  • Hitachi-shi, Ibaraki, Japan
  • Hitacinaka-shi, Ibaraki, Japan
  • Marugame-shi, Kagawa, Japan
  • Takamatsu-shi, Kagawa, Japan
  • Kagoshima-shi, Kagoshima, Japan
  • Kanoya-shi, Kagoshima, Japan
  • Kawasaki-shi, Kanagawa, Japan
  • Yokohama-shi, Kanagawa, Japan
  • Kumamoto-shi, Kumamoto, Japan
  • Yashiro-shi, Kumamoto, Japan
  • Kyoto-shi, Kyoto, Japan
  • Nagasaki-shi, Nagasaki, Japan
  • Sasebo-shi, Nagasaki, Japan
  • Oita-shi, Oita, Japan
  • Okayama-shi, Okayama, Japan
  • Shimajiri-gun, Okinawa, Japan
  • Daito-shi, Osaka, Japan
  • Fujiidera-shi, Osaka, Japan
  • Hirakata-shi, Osaka, Japan
  • Kishiwada-shi, Osaka, Japan
  • Osaka-shi, Osaka, Japan
  • Sakai-shi, Osaka, Japan
  • Suita-shi, Osaka, Japan
  • Takatsuki-shi, Osaka, Japan
  • Toyonaka-shi, Osaka, Japan
  • Saga-shi, Saga, Japan
  • Ageo-shi, Saitama, Japan
  • Kumagaya-shi, Saitama, Japan
  • Tokorozawa-shi, Saitama, Japan
  • Otsu-shi, Shiga, Japan
  • Shizuoka-shi, Shizuoka, Japan
  • Ashikaga-shi, Tochigi, Japan
  • Otawara-shi, Tochigi, Japan
  • Shimotsuga-gun, Tochigi, Japan
  • Shimotsuke-shi, Tochigi, Japan
  • Tokushima-shi, Tokushima, Japan
  • Hachioji-shi, Tokyo, Japan
  • Kodaira-shi, Tokyo, Japan
  • Kokubunji-shi, Tokyo, Japan
  • Meguro-ku, Tokyo, Japan
  • Minato-ku, Tokyo, Japan
  • Mitaka-shi, Tokyo, Japan
  • Ota-ku, Tokyo, Japan
  • Setagaya-ku, Tokyo, Japan
  • Shinagawa-ku, Tokyo, Japan
  • Wakayama-shi, Wakayama, Japan
  • Yamagata-shi, Yamagata, Japan
  • Shimonoseki-shi, Yamaguchi, Japan
  • Kofu-shi, Yamanashi, Japan
08

References and documents

Publications

  • Miwa H, Uedo N, Watari J, Mori Y, Sakurai Y, Takanami Y, Nishimura A, Tatsumi T, Sakaki N. Randomised clinical trial: efficacy and safety of vonoprazan vs. lansoprazole in patients with gastric or duodenal ulcers - results from two phase 3, non-inferiority randomised controlled trials. Aliment Pharmacol Ther. 2017 Jan;45(2):240-252. doi: 10.1111/apt.13876. Epub 2016 Nov 27. PubMed 27891632 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2011, a primary completion of Dec 2012 and a completion of Dec 2012. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 16, 2011
First posted
Oct 17, 2011
Start
Nov 2011
Primary completionActual
Dec 2012
CompletionActual
Dec 2012
Last update
Jun 21, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 21, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01452711
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
Oct 17, 2011
Start date
Nov 2011
Primary completion
Dec 2012
Completion
Dec 2012
Last update
Jun 21, 2013

Study contacts

Senior Manager
study director · Takeda

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vonoprazan

Start the discussion